Drug intelligence / Profile preview

cytarabine + thiotepa + fludarabine + busulfan

Development stage: Unknown
Lead developer: Adienne S.r.l. S.U.
Modality: Small Molecules
Administration: Intravenous

Overview

A myeloablative conditioning regimen used before allogeneic stem cell transplantation, particularly for patients with acute myeloid leukemia (AML). This combination has demonstrated promising outcomes in cord blood and haploidentical stem cell transplantation. The regimen provides significant anti-leukemic effects with thiotepa and busulfan having good penetration into the central nervous system. Studies have shown that this regimen provides lower relapse rates compared to other conditioning regimens like busulfan plus cyclophosphamide (BuCy), while maintaining similar survival outcomes.

Targets

DNA polymerase familydsDNA (Double-stranded DNA)DNA

Beyond the preview

Go deeper on cytarabine + thiotepa + fludarabine + busulfan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cytarabine + thiotepa + fludarabine + busulfan.

Explore the full profile